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ABSTRACT
Cytokines IL-17 and IL-22 play pivotal roles in host defense against microbes and in the development of chronic
inflammatory diseases. These cytokines are produced by cells that are often located in epithelial barriers, including subsets
of T cells and innate lymphoid cells. In general, IL-17 and IL-22 can be characterized as important cytokines in the rapid
response to infectious agents, both by recruiting neutrophils and by inducing the production of antimicrobial peptides.
Although each cytokine induces an innate immune response in epithelial cells, their functional spectra are generally
distinct: IL-17 mainly induces an inflammatory tissue response and is involved in the pathogenesis of several autoimmune
diseases, whereas IL-22 is largely protective and regenerative. In this review, we compare IL-17 and IL-22, describing
overlaps and differences in their cellular sources as well as their regulation, signaling, biological functions and roles
during disease, with a focus on the contribution of these cytokines to the gut mucosal barrier during bacterial infection.
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INTRODUCTION
Leukocytes constitute the second largest class of cells found
within the intestine, second only to epithelial cells (Artis 2008;
Ma et al. 2008). Within the intestinal mucosa, leukocyte types
are segregated into two distinct anatomic areas: the lamina
propria (LP) and the epithelium (Hooper and Macpherson 2010;
Maynard et al. 2012). The LP harbors adaptive immune cells such
as T cells and B cells, as well as innate immune cells, includ-
ing dendritic cells (DCs), macrophages and eosinophils. In con-
trast, specific subsets of cells called intraepithelial lymphocytes
(IELs) are found associated with the epithelial layer, in particu-
lar at the basement membrane between enterocytes (Cheroutre,
Lambolez and Mucida 2011). Gut IELs are almost exclusively
T cells, as originally estimated based on histological sections
(Darlington and Rogers 1966). In addition, CX3C-chemokine re-
ceptor 1 (CX3CR1)+ macrophages and DCs reside within the in-
testinal epithelial layer andhave the capacity to sample antigens
in the gut and promote appropriate T-cell responses (Bogunovic
et al. 2009; Schulz et al. 2009).
The gastrointestinal (GI) tract is home to trillions of mi-
crobes, comprising thousands of species that reside within the
lumen (Mowat and Agace 2014). These microbes, collectively re-
ferred to as the gut microbiota, vary in composition and num-
ber along the length of the GI tract (Mowat and Agace 2014).
Althoughmost intestinalmicrobes are beneficial and live symbi-
otically with the host, disruption of the epithelial barrier or inva-
sion by pathogenicmicrobes elicits a complex immune response
involving the intestinal epithelium and leukocytes. Restoration
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of epithelial integrity and eradication of invading microbes are
orchestrated through the activity of cytokines and chemokines,
which enable epithelial cells and leukocytes to communicate,
and promote responses such as cell migration, differentiation,
replication or activation of cell-intrinsic defenses (Matthews,
Weight and Parkos 2014).
Intestinal cytokine responses comprise complex signaling
networks, wherein cytokines regulate one another (Garlanda,
Dinarello and Mantovani 2013; Manzanillo, Eidenschenk and
Ouyang 2015). As such, disrupting one particular cytokine re-
sponse can lead to different outcomes depending on the cell
types and the intestinal regions involved, as well as on the gut
microbiota. Recognizing the context of these signaling networks
can help in understanding the various roles of intestinal cy-
tokines under different conditions. In this review, we discuss
recent findings on the interleukin (IL-) 17 and IL-22 pathways,
focusing on their roles in intestinal homeostasis and in the host
response to infection. Furthermore, we describe the various cell
types that produce IL-17 and IL-22 during bacterial infection, and
we discuss how these responses are activated and regulated by
pattern recognition receptor (PRR)-dependent pathways. Finally,
we examine the importance of IL-17 and IL-22 responses in me-
diating gut immunity to bacterial-induced colitis.
IL-17 and IL-22 are related, but distinct
cytokines
Cytokines are secreted proteins that play an important role in
intercellular communication. In addition to orchestrating the
immune response to pathogens, cytokines also regulate wound
healing, angiogenesis and physiological and pathological tissue
reorganization (Zhu and Emerson 2002; Leoni et al. 2015; Kreuger
and Phillipson 2016). Cytokines elicit biological effects by bind-
ing to the extracellular moiety of specific transmembrane recep-
tor proteins on the outer membrane of cells. This binding trig-
gers a signaling pathway, which leads to functional changes in
these cells. Cytokines are grouped into families based on simi-
larities in genome location, gene structure, structure of the se-
creted protein and the receptor(s) the cytokine engages. IL-17
and IL-22 are leukocyte-derived cytokines that primarily impact
epithelial cells in tissues such as the gut, the lung and the skin
(Blaschitz and Raffatellu 2010; Qu et al. 2013).
IL-17 belongs to the IL-17 cytokine family, whereas IL-22 is
a member of the IL-10 cytokine family (Park et al. 2005). The in
vivo effector functions of IL-17 and IL-22 are crucial to maintain-
ing mucosal immunity against specific pathogens and include
induction of antimicrobial proteins, recruitment of neutrophils
to sites of bacterial invasion and enhancement of mucosal bar-
rier repair and maintenance by stimulating epithelial cell pro-
liferation and tight junction protein production (Ye et al. 2001a;
Liang et al. 2006; Aujla et al. 2008; Raffatellu et al. 2008; Zheng
et al. 2008; Conti et al. 2009; Pickert et al. 2009).
There are sixmembers of the IL-17 family: IL-17A (commonly
referred to as IL-17), IL-17B, IL-17C, IL-17D, IL-17E (also known
as IL-25) and IL-17F (Kolls and Linden 2004; Iwakura et al. 2011).
These cytokines are often co-expressed and can formhomo- and
heterodimers. In 1995, IL-17 receptor A (IL-17RA) was identified
as a new cytokine receptor for IL-17A and was later found to
be part of a new cytokine receptor family (Yao et al. 1995). The
IL-17 receptor family now consists of five members (IL-17RA,
RB, RC, RD and RE), all of which, like their ligands, share se-
quence homology (Aggarwal and Gurney 2002). IL-17RA is ex-
pressed on a wide range of tissues and cell types. Upon stimu-
lation with IL-17, IL-17RA initiates the activation of downstream
signaling pathways to induce the production of proinflamma-
tory molecules. However, IL-17RA alone is insufficient to medi-
ate IL-17 signaling. Further evaluation revealed that IL-17 signals
through a heterodimeric receptor complex composed of IL-17RA
and IL-17RC (Toy et al. 2006; Rickel et al. 2008; Song et al. 2011).
It is proposed that the binding of ligand to the first IL-17 recep-
tor subunit alters the affinity and specificity of the second bind-
ing event, thereby promoting the formation of a heterodimeric,
rather than a homodimeric, receptor complex (Ely, Fischer and
Garcia 2009; Liu et al. 2013). IL-17 receptors work through a path-
way that depends on ACT1s (also referred to as CIKS) and ac-
tivates NF-κB and MAP kinases for the induction of proinflam-
matory mediators such as IL-6, IL-8, granulocyte-macrophage
colony-stimulating factor (GM-CSF), some chemokines (CXCL1,
CXCL10, CCL2, CCL7, CCL20) and matrix metalloproteinase-3
(MMP3) and MMP13 (Fossiez et al. 1996; Gaffen 2009).
IL-22 signals through a heterodimeric receptor comprised
of the broadly expressed IL-10R2 subunit and the more re-
stricted IL-22R1 subunit (Dumoutier, Louahed and Renauld 2000;
Dumoutier et al. 2000; Xie et al. 2000). IL-22R1 is mainly ex-
pressed on intestinal and respiratory epithelial cells, on ker-
atinocytes and on hepatocytes, but not on cells of hematopoi-
etic origin (Dudakov, Hanash and van den Brink 2015). IL-22
binds first to IL-22R1, and then the IL-22–IL-22R1 complex binds
IL-10R2 to propagate downstream signals (Logsdon et al. 2002;
Li et al. 2004). IL-22 signals through the JAK-STAT pathway,
inducing phosphorylation of the kinases JAK1 and TYK2, as
well as of the transcription factors STAT1, STAT3 and STAT5
(Dumoutier, Louahed and Renauld 2000; Dumoutier et al. 2000;
Xie et al. 2000; Pestka et al. 2004). Triggering this signaling path-
way allows IL-22 to induce the expression of various tissue-
specific genes including those that encode proteins involved
in tissue inflammation, immunosurveillance and homeostasis
(Wolk et al. 2004; Liang et al. 2006, 2010; Zheng et al. 2008). By elic-
iting various innate defense mechanisms from epithelial cells,
IL-22 is essential for host defense at mucosal surfaces against
extracellular pathogens such as bacteria and yeast (Zheng et al.
2007, 2008; Aujla et al. 2008; Sonnenberg et al. 2012). In general, IL-
22 acts to strengthen epithelial barrier functions and is involved
in tissue homeostasis aswell as in tissue repair andwound heal-
ing. However, excessive or prolonged production of IL-22 can
cause pathology, such as psoriasis-like skin inflammation (Ma
et al. 2008).
IL-17 was initially found to be secreted by a subset of CD4+
T cells termed Th17 cells, which also secrete the cytokines IL-22
and IL-21 (Harrington et al. 2005; Langrish et al. 2005; Park et al.
2005; Korn et al. 2007; Zheng et al. 2007). However, recent stud-
ies identified several other cell types that contribute to IL-17 and
IL-22 production (Wolk et al. 2002, 2011; Kondo et al. 2009; Ortega
et al. 2009), including activated CD4+ T cells (Harrington et al.
2005; Park et al. 2005; Wolk et al. 2011), CD8+ T cells (Kondo et al.
2009; Ortega et al. 2009), as well as various innate lymphoid cells
(ILCs) such as natural killer (NK) cells (Hughes et al. 2010; Pandya
et al. 2011), NKT cells (Rachitskaya et al. 2008), lymphoid tissue
inducer (LTi) cells (Cupedo et al. 2009; Crellin et al. 2010) and LTi-
like cells (Luci et al. 2009; Kim et al. 2011) (Table 1). The role of
these cells in secreting IL-17 and IL-22 is discussed in detail be-
low.
Increasing evidence shows that IL-17 and IL-22 can be pro-
tective against infections, largely by the following two mecha-
nisms. The first involves production of antimicrobial peptides,
which is largely dependent on the synergistic action of IL-17
and IL-22 on epithelial cells (Wolk et al. 2004; Liang et al. 2006;
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Table 1. Cell types that secrete IL-17 and/or IL-22.
Cell type
Cytokine
secreted
Transcription
factor Surface phenotype
Human/mouse
studies Ref
Th17 IL-17, IL-22 RORγ t CD4+, CCR4+, CCR6+, CXCR3−,
CD161+, IL23R+
Human and
mouse studies
Cosmi et al. (2008), Kleinschek
et al. (2009); Park et al. (2005)
Th22 IL-22 Unknown
(AHR?)
CD4+, CCR4+, CCR6+, CCR10+ Human Eyerich et al. (2009);
Trifari et al. (2009)
Tc22 IL-22 Unknown CD4+, CD8+, IL-21R+ Human Nograles et al. (2009)
Tc17 IL-17 Unknown CD8+, CD45RB+, CD38+, CD103+,
CCR6+
Mouse Yen et al. (2009)
γ δ cells IL-17, IL-22 AP1 CD27−, CD28−, NKP80+, CD45RA+,
CD158+
Human and
mouse
Peng et al. (2008), Riera-Sans
and Behrens (2007), Shibata
et al. (2008)
NKT IL-17, IL-22 ROR CD3+, CD56+ Mouse Rachitskaya et al. (2008)
LTi IL-17, IL-22 RORC CD3−, CD56−, CD161+, NKp44−,
CD117+, CD127+
Human Cupedo et al. (2009)
NKp46+ IL-17, IL-22 RORC CD3-, CD56+, NKp44+ NKp46+,
NKG2D+, CD117+, CD127+
Mouse Satoh-Takayama et al. (2008)
NK22 IL-22 Unknown CD3−, CD56+, NKp44+ CD117+,
CD127+
Mouse Norian et al. (2009)
Zheng et al. 2008; Feng et al. 2009). The second mechanism in-
volves IL-17 and IL-22 inducing gut and lung epithelial cells
to express chemokines that attract granulocytes, particularly
neutrophils, to sites of infection (Albanesi et al. 2000; Nograles
et al. 2008). Despite their protective role against extracellular
pathogens, IL-17 and IL-22 may also be detrimental when they
are not tightly regulated. Indeed, these cytokines contribute to
the pathology observed in several autoimmune and chronic in-
flammatory diseases, including psoriasis, asthma and inflam-
matory bowel disease (Teunissen et al. 1998; Andoh et al. 2005;
Chan et al. 2006; Wolk et al. 2007; McKinley et al. 2008).
IL-17 and IL-22 are regulated by
PRR-dependent pathways
The innate immune system is crucial for controlling infectious
agents. By using a wide range of innate immune sensors termed
pattern recognition receptors (PRRs), the host recognizes general
pathogen-associatedmolecular patterns (PAMPs), initiating a re-
sponse that limits the pathogen and alerts the adaptive immune
system (Fig. 1). Two of the most important PRR protein fami-
lies are the membrane-bound Toll-like receptors (TLRs) and the
cytosolic Nod-like receptors (NLRs). Mammals have many TLRs,
each of which recognizes certain PAMPs. For example, TLR4 rec-
ognizes lipopolysaccharide, a major component of the Gram-
negative bacterial cell wall (Lu, Yeh and Ohashi 2008). TLR2,
which is also located on the cell membrane, recognizes bacte-
rial surface lipoproteins (Kang et al. 2009), whereas TLR9, which
is located in the membrane of cellular organelles known as en-
dosomes, recognizes non-methylated CpG sequences present in
bacterial DNA (Latz et al. 2004). When a TLR binds to its ligand,
host-cell adaptor proteins, such as Myeloid differentiation pri-
mary response gene 88 (MyD88), associate with the cytoplas-
mic part of the receptor, and downstream signaling is initiated
(Medzhitov et al. 1998) (Fig. 1).
TLR-dependent pathways are important for host defense
against bacterial pathogens (Charrel-Dennis et al. 2008; Kawai
and Akira 2011; Wang and Liu 2016), including pathways that
control IL-17 and IL-22 responses (Abt et al. 2016) (Fig. 1). For
example, it was recently shown that TLR7 stimulation with the
synthetic ligand resiquimod (R848) induces IL-23 expression fol-
lowed by a burst of IL-22 secretion by ILCs, leading to expression
of the antimicrobial lectin REG3γ and restoration of colonization
resistance against vancomycin-resistant Enterococcus (VRE) (Abt
et al. 2016).
Interleukin-23 is a heterodimeric cytokine comprised of the
subunits p19 and p40 (Hunter 2005), and is a crucial upstream
regulator of IL-17 and IL-22 expression in vivo (Dubin and Kolls
2007; Godinez et al. 2009; Gasse et al. 2011; Cox et al. 2012). In
a mouse model of Klebsiella pneumoniae lung infection, bacterial
stimulation of TLR4 on DCs results in IL-23 production (Happel
et al. 2003). IL-23, in turn, triggers rapid production of IL-17 and
IL-22 by T cells (Ye et al. 2001a,b; Happel et al. 2005; Aujla et al.
2008), which is required for efficient neutrophil recruitment in
this model. Similarly, injection of Escherichia coli into the peri-
toneal cavity of naı¨ve mice triggers IL-23 production in a TLR4-
dependent manner, and the resulting secreted IL-17 largely
originates from γ δ T cells (Shibata et al. 2007). TLR4 also modu-
lates IL-23 expression in mouse bone marrow-derived conven-
tional DCs during Salmonella enterica serovar Enteritidis infec-
tion (Siegemund et al. 2007). In the presence of intestinal inflam-
mation, IL-23 stimulates T cells in the murine intestinal mu-
cosa to produce IL-17 and IL-22, promoting neutrophil recruit-
ment in response to S. enterica serovar Typhimurium infection
(Godinez et al. 2009). The TLR/IL-23/IL-17 axis is also an impor-
tant player in vaccine-induced protection, wherein TLR4 signal-
ing is required for vaccine-induced immunity to Bordetella per-
tussis in mice (Higgins et al. 2006). In this model, production of
IL-23 and IL-1β by DCs contributed to Th17 cell differentiation,
while increases in IL-17 levels led to enhanced bacterial clear-
ance and macrophage bactericidal activity in a dose-dependent
fashion (Higgins et al. 2006).
All TLRs except TLR3 require MyD88 as an adaptor to medi-
ate signal transduction (Gay et al. 2014). MyD88 appears to be
crucial for inducing maximal expression of IL-17 and IL-22 in
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Figure 1. Bacterium-induced signaling in antigen-presenting cells (APCs) leads to IL-23 production and subsequent activation of IL-17 and IL-22-producing cells.
APCs, for instance DCs and macrophages, express PRRs on their surface, such as TLRs, and intracellular receptors in their cytosol, such as NLRs. These PRRs rec-
ognize conserved microbial-associated molecular motifs and PAMPs, including LPS, lipoproteins, and CpG oligodeoxynucleotides. When a TLR binds to its cognate
PAMP, host-cell adaptor molecules such as MyD88, TIRAP and TRIF are recruited, and downstream signaling is initiated. The resulting activation of nuclear factor-κB
(NF-κB) promotes transcription of a range of genes coding for proinflammatory cytokines, including IL-23, which trigger the production of IL-17 and IL-22 in cell subsets
including Th17, γ δ T and ILC3.
the gut and the lung (Lebeis et al. 2007; Gibson et al. 2008; Zhang
et al. 2009; Keestra et al. 2011). In the S. Typhimurium colitis
model, Myd88−/− mice exhibit a delayed mucosal inflammatory
response and blunted IL-17 and IL-22 levels when compared to
wild-type controls (Keestra et al. 2011). During gut infection with
Citrobacter rodentium,Myd88−/− mice display increasedmortality,
intestinal pathology and systemic bacterial spread; whether this
is associated with IL-17 and IL-22 responses has yet to be eluci-
dated (Lebeis et al. 2007; Gibson et al. 2008). In the lung,Myd88−/−
mice exhibit a reduced innatemucosal IL-17 response during in-
fection with Chlamydia muridarum (Zhang et al. 2009). Moreover,
in a T-cell transfer model of colitis, Myd88−/− CD4+ T cells ex-
press lower levels of IL-17 than wild-type CD4+ T cells, indicat-
ing a direct role forMyD88 signaling inmodulating T-cell effector
function (Fukata et al. 2008).
Whether MyD88-dependent regulation of T-cell-induced col-
itis is due to TLR signaling or IL-1 family cytokine signaling re-
mains unclear. Fukata et al. (2008) showed that CD4+CD45Rbhigh
T cells express significant levels of TLRs, suggesting a role
for TLR signaling by T cells in Th17 differentiation and in
the development of inflammatory bowel disease. On the other
hand, Chang et al. (2013) demonstrated that MyD88 medi-
ates IL-1 signaling in CD4+ T cells for the upregulation of IL-
23R by IL-23, which expands committed Th17 cells via mTOR
activation.
The cytosolic NLRs are another class of PRRs activated during
enteric infections, recognizing bacterial PAMPs in the cystosol
(Fig. 1) (Inohara and Nunez 2001). NLRs are classified into several
subfamilies on the basis of their amino-terminal domain (Ting
et al. 2008), including the CARD-containing nucleotide-binding
oligomerization domain proteins (e.g, NOD1, NOD2 and NLRC4),
the pyrin domain-containing proteins (e.g. NLRP3) and the BIR-
containing proteins (also known as NAIPs or BIRCs). NOD re-
ceptors recognize fragments of peptidoglycan; specifically, NOD1
recognizes γ -D-glutamyl-meso-diaminopimelic acid (iE-DAP), a
molecule produced byGram-negative bacteria (Chamaillard et al.
2003; Girardin et al. 2003a,b), whereas NOD2 recognizesmuramyl
dipeptide (MDP), which is present in both Gram-positive and
Gram-negative bacteria (Girardin et al. 2003a,b). Several NLRs
have been shown to have a role in inflammatory diarrhea. Mice
deficient in Nod1 and Nod2 exhibit a delayed intestinal inflam-
matory response in colitis models employing S. Typhimurium or
C. rodentium (Geddes et al. 2011). In the cecal tissue of thesemod-
els, when compared towild-typemice, absence of bothNod1 and
Nod2 results in reduced amounts of IL-17 and IL-22, as well as
the antimicrobial proteins RegIIIγ and lipocalin 2 (Geddes et al.
2011).
NLRP3 and NLRC4 trigger the formation of cytosolic protein
complexes called inflammasomes, which in turn regulate the
maturation of the cytokines IL-1β and IL-18 (Latz, Xiao and Stutz
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2013). Inflammasomes are activated in response to a variety of
signals that indicate injury to the host, including tissue dam-
age, metabolic stress and infection. NLRP3 responds to a wide
range of PAMPs and DAMPs, including bacterial messenger RNA,
bacterial DNA:RNA hybrids, MDP, DNA and RNA viruses, fungi,
protozoa, ATP, uric acid crystals, silica, aluminum hydroxide, as-
bestos and bee venom (Kanneganti et al. 2006; Dostert et al. 2008;
Hornung et al. 2008; Marina-Garcia et al. 2008; Sander et al. 2011;
Franchi et al. 2014; Kailasan Vanaja et al. 2014; Sha et al. 2014).
The NLRC4 inflammasome is activated by flagellin (Franchi et al.
2006; Miao et al. 2006) and the inner rod proteins of type III se-
cretion systems (Miao et al. 2010). The inflammasome is a key
regulator of immune responses in the gut and inflammasome-
dependent IL-17 production has been implicated in protection
from bacterial and fungal infection. IL-1β produced by NLRP3
inflammasome activity has been shown to mediate a protective
Th17 response against the E. coli heat-labile enterotoxin in mice,
indicating that NLRP3 activation could regulate IL-17 responses
(Brereton et al. 2011). Inflammasome-mediated IL-1β plays a crit-
ical role in promoting Ag-specific Th17 cells and in generating
shielding immunity against B. pertussis infection (Dunne et al.
2010). It has also been demonstrated that caspase-1 and ASC
are important in the defense against Candida through IL-1β and
IL-18 expression and consequent induction of antifungal Th1
and Th17 responses (van de Veerdonk et al. 2011). Moreover, two
recent studies (Levy et al. 2015; Nowarski et al. 2015) demon-
strated that epithelial inflammasome activation and IL-18 secre-
tion can control intestinal homeostasis or induce autoinflam-
mation. ILC3 cells are triggered to secrete IL-22, regulating IL-18
expression in epithelial cells, in turn modulating homeostasis
and inflammation. Finally, the IL-18 pathway seems to take part
in the host’s defense against C. rodentium infection downstream
of IL-22 (Munoz et al. 2015).
IL-17 and IL-22-producing cells in response to
acute infection
T helper cells
During the immune response to infection, IL-17A/F and IL-22 are
often produced at the same time and at high levels in inflamed
tissues. In general, a broad variety of T cells and other leuko-
cytes secrete IL-17 and/or IL-22 (Table 1). Themost characterized
IL-17/IL-22-secreting cells are T helper 17 (Th17) cells (Korn et al.
2009). Th17 cells were first described as peripheral CD4+ T cells
that differentiate into a distinct lineage in a GATA-3 and T-bet-
independent fashion (Harrington et al. 2005; Park et al. 2005). This
T-cell population is abundant at homeostasis in gut-associated
tissues, particularly in the LP, and is defined by expression of
the transcription factor RORγ t (Ivanov et al. 2006, 2008). Th17-
cell differentiation depends on IL-6 and on transforming growth
factor β (TGF-β) (Bettelli et al. 2006; Ivanov et al. 2006; Mangan
et al. 2006). Signal transduction downstream of IL-6 and TGF-
β, including STAT3 activation downstream of the IL-6 receptor,
induces expression of RORγ t, which promotes transcription of
Il17a and Il17f (Ivanov et al. 2006; Harris et al. 2007; Yang et al.
2007).
In addition to IL-6 and TGFβ, commensalmicrobes are neces-
sary for the development of Th17 cells (Atarashi et al. 2008; Hall
et al. 2008), as Th17 cells are absent in germ-free mice (Ivanov
et al. 2006). Monoassociation of germ-free mice with commen-
sal microbes of the class Clostridiales known as ‘Candidatus
Arthromitus’ or ‘segmented filamentous bacteria’ (SFB) is suffi-
cient to induce Th17-cell development (Gaboriau-Routhiau et al.
2009; Ivanov et al. 2009; Wu et al. 2010). Colonization of mice
with SFB results in rapid upregulation of serum amyloid A (SAA)
proteins in intestinal epithelial cells, which is both necessary
and sufficient to directly promote proliferation of RORγ t+ CD4+
T cells and IL-17 production (Sano et al. 2015). Moreover, IL-22 de-
rived from group 3 innate lymphoid cells (ILC3) seems to poten-
tiate expression of SAAs by intestinal epithelial cells (Atarashi
et al. 2015; Sano et al. 2015). CD11c+ myeloid cells and adhesion-
elicited epithelial cell production of reactive oxygen species also
contribute to SAA-dependent production of Th17-promoting cy-
tokines (Atarashi et al. 2015).
TLR, inflammasome and dectin signaling each appear to be
required for SFB-mediated Th17-cell development, suggesting
that there may be redundant innate signals (Ivanov et al. 2009).
Additionally, a recent study suggests that intimate adhesion
of SFB to the epithelium is important for Th17 development
(Atarashi et al. 2015). As SFB have not been identified in the hu-
man gut, it is not clear yet whether microbes contribute to Th17
development in humans. Nevertheless, Atarashi et al. (2015)
showed that Th17 cells develop in mice upon infection with the
human pathogen Enterohemorragic E. coli O157:H7, as well as
after administration of a mixture of adherent human commen-
sal strains belonging to different species, including Clostridium,
Bifidobacterium, Ruminococcus and Bacteroides isolated from fecal
samples of a patient with ulcerative colitis.
The Th17 response is a crucial arm of mucosal immunity
against bacterial pathogens in the lung and the intestine. These
cellsmediate protection in a number ofmodels of lung infection,
including K. pneumoniae, Pseudomonas aeruginosa, Shigella flexneri
and severalMycobacterium species (Khader et al. 2007; Umemura
et al. 2007; Aujla et al. 2008; Priebe et al. 2008). In the GI tract,
Th17 cells increase host resistance against Helicobacter pylori,
C. rodentium and S. Typhimurium (Wu et al. 2007; Raffatellu et al.
2008; Ivanov et al. 2009; Velin et al. 2009; Sellge et al. 2010). For in-
stance, in a simian immunodeficiency virus infection model in
macaques, depletion of gut CD4+ Th17 cells led to increased sys-
temic dissemination of S. Typhimurium (Raffatellu et al. 2008).
Similarly, depletion of CD3+ T cells in the streptomycin-treated
mouse model of S. Typhimurium colitis resulted in a blunted in-
nate IL-17 response and an associated decrease in mucosal pro-
tection against the pathogen (Raffatellu et al. 2008; Godinez et al.
2009). A subset of LP CD4+ T cells that express IL-17 and IL-22
during the innate phase of infection with S. Typhimurium and
C. rodentium has subsequently been identified and termed innate
Th17 (iTh17) cells (Geddes et al. 2011). Finally, two novel subsets
of Th17 cells have recently been identified: a proinflammatory
subset that produces GM-CSF (Codarri et al. 2011; El-Behi et al.
2011) and a regulatory subset that produces IL-10 (Esplugues
et al. 2011). The role of these cell subsets in response to infec-
tion is unknown.
Beyond the mucosa, SFB also trigger development of sys-
temic Th17 cells, which can be detrimental; for example, by
triggering spontaneous arthritis in a mouse model (Wu et al.
2010). Similarly, monoassociation of mice with SFB exacerbates
the course of experimental autoimmune encephalomyelitis (Lee
et al. 2011), a paralytic autoimmune disease induced by immu-
nization with myelin protein and mediated by Th17 cells. Thus,
depending on the setting, Th17 cells can be protective, but they
can also initiate or exacerbate autoimmunity.
In addition to Th17 cells, a second T helper cell population
was recently described as a major source of IL-22 in human
tissue. Named Th22 cells, this population expresses the CCR4
and CCR10 chemokine receptors, and is enriched for during in-
flammatory skin diseases (Nograles et al. 2008; Duhen et al. 2009;
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Eyerich et al. 2009; Trifari et al. 2009). In contrast to Th17 cells,
which are able to secrete both IL-17 and IL-22, Th22 cells do not
secrete IL-17. A third group of adaptive immune cells that pro-
duce IL-17 and/or IL-22 are CD8+ T cells (Kondo et al. 2009; Ortega
et al. 2009). Similar to Th17 cells, a population of CD8+ T cells
produces IL-17, but it is unclear whether these cells coproduce
IL-22 and whether they represent a functionally distinct subset
(Tc17 cells) of CD8+ T cells (Shin et al. 1999). Furthermore, there is
evidence for a subgroup of CD8+ T cells that produces IL-22, but
not IL-17 (Tc22 cells) (Nograles et al. 2009). The discovery of these
distinct lineages of leukocytes that produce different subsets of
cytokines emphasizes that production of IL-17 and IL-22 is regu-
lated by distinct processes, underlining the potential complexity
of these responses in different models of infection and autoim-
munity.
γ δ T cells
γ δ T cells are an innate immune cell population that plays im-
portant roles at the mucosal barrier. These cells are predomi-
nantly found in the intestinal epithelial lymphocyte compart-
ment of the intestinal mucosa and they can be classified into
an IFN-γ -producing subset or an IL-17 and IL-22-producing sub-
set (Cua and Tato 2010). CD27− RORγ t+ γ δ T cells secrete IL-17
and/or IL-22 when stimulated with IL-23, IL-1β, or with a cock-
tail of phorbol 12-myristate-13-acetate (PMA) and ionomycin
(Jensen et al. 2008; Ribot et al. 2009). Relatedly, IL-23 is sufficient
to induce IL-17A production in γ δ T cells purified from the peri-
toneum of infected mice (Shibata et al. 2007). Of particular note,
γ δ T cells can rapidly produce IL-17A upon TLR and/or cytokine
stimulation. Early production of IL-17A was observed during
E. coli infection, where peritoneal IL-17A was found as early as 1
h after infection (maximal production at 6 h), and large amounts
of neutrophils were recruited by 24 h post-infection (Shibata
et al. 2007). Similarly, IL-17A production by peritoneal γ δ T cells is
rapidly induced after injection of heat-killedmycobacteria (Mar-
tin et al. 2009) or after sepsis due to cecal puncture (Flierl et al.
2008).
In the skin, IL-17A-producing γ δ T cells can promote the
formation of abscesses and granulomas to help mediate con-
tainment of microbial infections (Cho et al. 2010). In cutaneous
Staphylococcus aureus infections, IL-17A-producing skin cells play
a critical role in the immune response against this pathogen.
In this setting, IL-17A helps to recruit neutrophils into skin ab-
scesses, to limit the size of abscesses and to reduce the num-
ber of S. aureus bacteria contained in these abscesses (Cho et al.
2010).
In Listeria monocytogenes infections, IL-17A-producing γ δ
T cells contribute to bacterial clearance by containing the bac-
teria within granulomas in the liver and by promoting the re-
cruitment of neutrophils and other myeloid cells (Hamada et al.
2008). In the absence of γ δ T cells or IL-17A, bacterial numbers in
the liver are more than 100-fold higher than in wild-type mice
(Hamada et al. 2008). Moreover, L. monocytogenes infection in γ δ T-
cell-deficientmice is associated with large inflammatory lesions
in the liver with necrotic hepatocytes (Mombaerts et al. 1993; Fu
et al. 1994) that are similar to those seen in IL-17A-deficient mice
(Hamada et al. 2008). IL-17RA and IL-23 are required to control L.
monocytogenes systemic infections and γ δ T cells are the principal
source of IL-17A early in infection (Meeks et al. 2009), although
CD4−8− αβ T cells also produce IL-17A in the peritoneum (Riol-
Blanco et al. 2010).
γ δ T cells can also be pathogenic. As with many T-cell pop-
ulations, inappropriate or sustained production of a proinflam-
matory cytokine can have negative consequences. Several au-
toimmune disease models have identified IL-17A-producing γ δ
T cells as being important in disease progression. For exam-
ple, in a model of collagen-induced arthritis, oligoclonal IL-17A-
producing γ δ T cells accumulate in the lymph nodes and joints
of collagen-injected mice (Roark et al. 2007). Depletion of Vγ4
γ δ T cells greatly reduces disease severity consistent with a sig-
nificant reduction in pathogenic anticollagen IgG2a (Roark et al.
2007). Moreover, in different models of neuroinflammation, γ δ
T cells play an important role in early activation and recruitment
of cells through the release of IL-17A. In experimental autoim-
mune encephalomyelitis (EAE), a mouse model of multiple scle-
rosis, γ δ T cells producing IL-17A accumulate in the brain (Jensen
et al. 2008; Sutton et al. 2009). Although γ δ cells alone are not suf-
ficient to reconstitute disease (αβ T cells are also required), γ δ-
deficient mice exhibit reduced EAE severity (Sutton et al. 2009).
In addition to producing IL-17A, γ δ T cells also inhibit CD4+ Treg
responses in EAE and reverse Treg suppression of αβ T cells in
vitro (Petermann et al. 2010).
The involvement of IL-17A-producing γ δ T cells in models of
microbial, autoimmune and inflammatory diseases underscores
their importance in the initiation and resolution of acute inflam-
matory responses in a variety of settings. Despite their small
numbers, γ δ T cells can have large effects on the type of immune
response and the disease outcome.
Innate lymphoid cells
The importance of a non-T-cell source for IL-22 was first demon-
strated in a C. rodentium infection model, in which wild-type
mice andmice that lack B and T cells (Rag2−/−) exhibited compa-
rable IL-22 production and normal host defense during the early
phase of infection (Zheng et al. 2008). These newly identified cells
were termed ILCs, then later categorized in human tonsils and
intestinal LP as ILC3 based on their production of IL-17 and IL-22
(Montaldo et al. 2014).
ILC3s can secrete IL-17 and IL-22 in response to IL-1β and/or
IL-23 due to their constitutive expression of IL-1R and/or IL-23R
(Spits and Cupedo 2012). ILCs, like B and T cells, are derived from
a common lymphoid progenitor. However, they represent a very
heterogeneous group of cells. All IL-17/IL-22-producing ILCs are
dependent on RORγ t for their development, including LTi cells
(Takatori et al. 2009), LTi-like ILCs (Buonocore et al. 2010), NKp46+
ILCs (Satoh-Takayama et al. 2008; Cella et al. 2009; Luci et al. 2009;
Sanos et al. 2009), invariant NKT cells (Doisne et al. 2011) and
mucosal-associated invariant T cells (Le Bourhis et al. 2011). Un-
like Th17 cells, antigenic priming is not required for activation
of LTi, LTi-like, NKp46+ ILCs and probably γ δ T cells; IL-23 stim-
ulation is often sufficient for inducing IL-17 and IL-22 secretion
by these cell types (Cua and Tato 2010; Cua and Sherlock 2011;
Le Bourhis et al. 2011).
The lineage of NKp46+ cells was first identified as a major
source of IL-22 in the intestine (Satoh-Takayama et al. 2008; Cella
et al. 2009; Luci et al. 2009). These cells do not co-express IL-
17, lack typical NK cell effector functions, and may or may not
express NK1.1. Interestingly, some of these NKp46+ cells also
express CD11c, an intergrin highly expressed by DCs. Surpris-
ingly, mice deficient in NKp46 are still capable of secreting IL-22
and are fully resistant to C. rodentium infection (Satoh-Takayama
et al. 2009). In the spleen and in the mesenteric lymph nodes,
another cell type, CD4+ LTi-like cells, produce IL-17 and IL-22
upon IL-23 stimulation (Takatori et al. 2009; Sonnenberg et al.
2011). LTi cells are also the building blocks of cryptopatches,
which are lymphoid structures found in both the small and
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large intestine. During C. rodentium infection, LTi cells are ma-
jor sources of IL-22 in the mesenteric lymph nodes (Sonnen-
berg et al. 2011). In contrast to NKp46+ ILCs, the develop-
ment of LTi cells is regulated by the lymphotoxin (LT) pathway
(Eberl et al. 2004; Satoh-Takayama et al. 2011). LT is a mem-
ber of the TNF core family and plays a critical role in reg-
ulation of mucosal immune responses (Fu and Chaplin 1999;
Tumanov, Christiansen and Fu 2007) and contributes to ef-
fector immune responses (Ware 2005; Wang et al. 2010). LT
also regulates DCs and CD4+ T-cell homeostasis in the steady
state, as well as determines the functions of these cells dur-
ing pathogenic challenge (Lewis et al. 2011; Upadhyay and
Fu 2013).
Consistent with a role for LTi cells during C. rodentium infec-
tion, mice deficient in the LT pathway are also more susceptible
(Spahn et al. 2004; Ota et al. 2011). Specifically, wild-type mice
treated with either an anti-IL-22 antibody or with LTβRFc fusion
protein show similar degrees of susceptibility to C. rodentium in-
fection, suggesting a connection between the LT and IL-22 path-
ways. Indeed, IL-22 induction in the colon during C. rodentium
infection is blocked when the LT pathway is deficient (Tumanov
et al. 2011). Taken together, these studies suggest a redundant
role for different ILC subsets during C. rodentium infection, and
the specific contribution of each cell type needs to be further
elucidated.
In addition to the aforementioned cell types, a pathogenic
population of Thy1+Sca1+ ILCs has been identified in the in-
flamed colon of mice in a H. hepaticus-induced colitis model
(Buonocore et al. 2010). These cells are negative for both NKp46
and CD4, but they are able to produce IL-17 and IL-22 upon stim-
ulation with IL-23, and drive the development of colitis (Buono-
core et al. 2010).
NON-LYMPHOID SOURCES OF IL-17 AND IL-22
Other potential sources of IL-17 and IL-22 include neutrophils
that are recruited to the site of infection (Zindl et al. 2013; Taylor
et al. 2014; Lee et al. 2015). In the dextran sodium sulfate coli-
tis model, IL-22-producing neutrophils were shown to be pro-
tective (Zindl et al. 2013). Intestinal pathology was alleviated
in DSS-treated Il22−/− mice transplanted with neutrophils from
wild-type mice, whereas neutrophils from Il22−/− mice had lit-
tle effect on disease progression (Zindl et al. 2013). During fun-
gal infection, IL-17-producing neutrophils are recruited to the
site of infection (Taylor et al. 2014), but whether neutrophils
produce IL-17 or not appears to be dependent on the infec-
tion model (Huppler et al. 2015). Proposed mechanisms for ac-
tivation of IL-17 and IL-22 production by neutrophils include
stimulation with cytokines such as IL-6 and IL-23, activation
of dectin-1 and 2, and through regulation of RORγ t and aryl-
hydrocarbon receptor (AhR) via activation ofmTOR (Werner et al.
2011; Zindl et al. 2013; Taylor et al. 2014; Chen et al. 2016). Future
studies are needed to further elucidate whether IL-17 and IL-
22 production by neutrophils contributes to the host response
to infection.
HOST DEFENSE AND PROTECTIVE FUNCTION
OF IL-17 AND IL-22 DURING INTESTINAL
INFECTION
In the gutmucosa, IL-17 and IL-22 have synergistic effects on the
induction of antimicrobial proteins by GI epithelial cells, which
have an important role in limiting dissemination of pathogens
and of commensal bacteria that could penetrate a disrupted ep-
ithelial barrier (Zheng et al. 2008; Ismail, Behrendt and Hooper
2009). IL-17 and IL-22 act in concert to orchestrate the mucosal
barrier, but the biological effects of these cytokines differ in
many aspects. IL-22 appears to be a novel type of immunemedi-
ator that increases the immune defenses of tissue cells, protects
tissues from damage and enhances their regeneration, whereas
IL-17A and IL-17F are typical proinflammatory mediators. Below
we discuss the effects of IL-17 and IL-22 primarily in the context
of gut infection.
IL-17
Themost prominent function of IL-17 is the recruitment of neu-
trophils to the site of infection, which is necessary for clear-
ing microorganisms (Ishigame et al. 2009). IL-17 stimulates tar-
get cells to produce neutrophil chemoattractants such as the
CXC chemokines IL-8 (CXCL8), CXCL1 and CXCL2, as well as
growth factors, including G-CSF and GM-CSF (Fig. 2). Neutrophil
recruitment is required for a rapid response (i.e. within 4–8 h)
against bacterial and fungal pathogens such as Citrobacter ro-
dentium, SalmonellaTyphimuriumandCandida albicans (Raffatellu
et al. 2008; Saijo et al. 2010; Geddes et al. 2011). IL-17 also syner-
gizes with other cytokines, such as IL-1, IL-6 and TNF-α, which
together promote activation of tissue infiltrating neutrophils to
effectively eliminate extracellular pathogens (Awane et al. 1999;
Dong 2008). Mice infected with C. rodentium mount protective
IL-17 responses, and disruption of IL-17 or its receptor leads
to exacerbated bacterial burden and dissemination, increased
disease susceptibility resulting from defective induction of CXC
chemokines and impaired neutrophil recruitment (Happel et al.
2005; Mangan et al. 2006). Importantly, administration of recom-
binant IL-17 into IL-17-deficient mice infected with C. roden-
tium restored neutrophilia at sites of inoculation (Happel et al.
2005), demonstrating the critical importance of the IL-23/IL-17
axis in host defense against extracellular bacterial infections.
Neutrophils are also an important first line of mucosal defense
against S. Typhimurium. In patients affected by primary neu-
trophil immunodeficiency (e.g. chronic granulomatous disease),
S. Typhimurium often disseminates from the gut, resulting in
bacteremia (Mouy et al. 1989; Winkelstein et al. 2000). In accor-
dance with these observations, Il17ra−/− mice exhibit reduced
neutrophil accumulation in the gut, and increased translocation
of S. Typhimurium to the mesenteric lymph nodes and spleen
(Raffatellu et al. 2008).
In addition to neutrophil recruitment, the IL-17 cytokine
family targets epithelial cells to induce antimicrobial responses
against extracellular pathogens and to promote tissue remodel-
ing (Ouyang, Kolls and Zheng 2008). An importantmechanism of
host defense in the intestine against bacterial pathogens is the
presence of tight junctions that maintain the integrity of the in-
testinal epithelium, thereby preventing bacterial translocation
(Macdonald and Monteleone 2005). In the gut epithelium, IL-17
stimulates the secretion of claudin 1 and claudin 2, proteins that
are involved in the formation of tight junctions, ultimately form-
ing a large, interconnecting network and maintaining intestinal
integrity (Moran et al. 2009; Dungan and Mills 2011). Although
IL-17 is largely considered proinflammatory, the cytokine may
also promote restoration of themucosal barrier and further con-
trol microbial translocation through the induction of tight junc-
tion proteins.
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Figure 2. Functions of IL-17 and IL-22 at epithelial surfaces. IL-17 and IL-22 are upregulated in response to infection with a variety of pathogens. These cytokines are
produced by subsets of cells, including γ δ T cells, ILC3 and Th17 cells, and elicit innate responses frommucosal epithelial cells. These responses include production of
mucins by goblet cells, upregulation of genes involved in wound healing (e.g. Bcl-2, c-Myc, cyclin D1), the secretion of antimicrobial molecules (e.g. S100A8, S100A9, REG
proteins, lipocalin-2) and the induction of proinflammatory mediators (e.g. TNF-α, IL-6, CXCL1, G-CSF) that contribute neutrophil recruitment at the site of infection.
The functions of both cytokines are overlapping and in part synergistic. While IL-22 is more potent in tissue protection, repair and induction of antimicrobial peptides,
IL-17 mediates stronger inflammatory responses by inducing other proinflammatory cytokines and the recruitment of neutrophils.
IL-22
The beneficial role of IL-22 during host defense has been studied
in several models of intestinal infection, including C. rodentium
(Ota et al. 2011) and Clostridium difficile (Hasegawa et al. 2014), as
well as during infection with VRE, a gut commensal bacterium
that causes bacteremia and endocarditis (Abt et al. 2016).
The functions of IL-22 during host defense against pathogens
can be summarized into three major categories (Fig. 2). First, by
promoting epithelial proliferation, IL-22 helps to maintain and
restore epithelial barrier function after infection. Second, IL-22,
together with other cytokines such as IL-17 or TNF-α, induces
the expression of antimicrobial proteins involved in host de-
fense in the skin, the airways and the intestine. Some antimi-
crobial proteins induced by IL-22 include lipocalin-2 and calpro-
tectin, which is a heterodimer of S100A8 and S100A9 (Behnsen
et al. 2014). These antimicrobial proteins sequester essential
metal ions from pathogens (Corbin et al. 2008; Liu et al. 2012),
a process known as nutritional immunity (Kehl-Fie and Skaar
2010). Therefore, IL-22-mediated induction of metal sequestra-
tion is an essential process in limiting growth and transloca-
tion of commensal microbes from the gut (Flo et al. 2004; Berger
et al. 2006; Raffatellu et al. 2009). IL-22 also promotes the pro-
duction of inflammatory mediators such as IL-1β, SAA and LPS-
binding protein (Wolk et al. 2007; Dalmas et al. 2014; Sano et al.
2015). During Klebsiella pneumoniae infection, IL-22 is essential for
the release of chemokines such as CXCL1, CXCL5 and CXCL9,
as well as IL-6 and G-CSF from airway epithelial cells (Aujla
et al. 2008). Overall, the primary function of IL-22 is to promote
mucosal barrier integrity, thus limiting bacterial replication and
dissemination.
During C. rodentium infection, IL-22 stimulates the produc-
tion of protective mucins from goblet cells (Sugimoto et al. 2008;
Turner, Stockinger and Helmby 2013) and induces the release
of the C-type lectins REG3β and REG3γ from intestinal epithe-
lial cells in the colon (Cash et al. 2006; Zheng et al. 2008). REG3γ
is a soluble C-type lectin produced by Paneth cells and epithe-
lial cells, which exerts its antimicrobial activity by interact-
ing directly with the bacterial cell wall (Cash et al. 2006). Mice
lacking IL-17 and IL-22 have reduced amounts of antimicro-
bial peptides and are highly susceptible to C. rodentium in-
fection; however, they can be rescued by treatment with re-
combinant REG3γ (Zheng et al. 2008). Microbiota-derived LPS
maintains basal expression of REG3γ in intestinal epithelial
cells and Paneth cells. Indeed, REG3γ is not detected in germ-
free mice (Cash et al. 2006; Mukherjee et al. 2014), and even
short-term antibiotic treatment impairs its expression, render-
ing mice susceptible to VRE infection, a defect that can be re-
verted by oral administration of LPS (Brandl et al. 2008). Sim-
ilarly, flagellin from commensal bacteria sensed by TLR5 ex-
pressed on CD103+ CD11b+ DCs found in the LP contributes
to the maintenance of REG3γ expression. Upon TLR5 activa-
tion, DCs produce IL-23, promoting IL-22 release by ILCs, and
therefore REG3γ expression in intestinal epithelial cells (Kin-
nebrew et al. 2010; Kinnebrew et al. 2012). The importance
of the IL-22-REG3γ axis against bacterial infections has been
recently demonstrated by Abt et al. (2016). Briefly, these au-
thors showed that Resiquimod (R848), a synthetic ligand for
TLR-7 that stimulates antiviral innate immune defenses, in-
duces IL-22 expression, restoring REG3γ and reestablishing col-
onization resistance against VRE in antibiotic-treated mice.
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Another mechanism by which IL-22 controls opportunis-
tic gut pathogens is by facilitating the binding of complement
component C3 to bacteria (Hasegawa et al. 2014). When the
intestinal mucosa is infected with C. difficile, this organism is
capable of translocating to other tissues, contributing to C.
difficile-induced mortality. However, IL-22 induces an increase of
C3 expression and secretion in the liver, which is mediated by
the STAT3 pathway. This process leads to a substantial increase
in systemic serum levels of C3,which in turnmediates enhanced
opsonization of translocated commensals and pathogens, and
their subsequent killing and clearance by neutrophils and
macrophages (Hasegawa et al. 2014).
Although IL-22 plays a beneficial role inmany infectionmod-
els, recent studies have shown that IL-22 production may also
be detrimental to the host. For instance, during S. Typhimurium
infection, IL-22 does not play a protective role, but is instead
exploited by the pathogen to colonize the gut to high levels
(Behnsen et al. 2014). IL-22 favors S. Typhimurium colonization
by inducing antimicrobial proteins that sequester metal ions.
As the pathogen is able to overcome metal starvation, it out-
competes related commensals such as Escherichia coli (Behnsen
et al. 2014). During Helicobacter pylori infection, IL-22 also con-
tributes to the development of gastric pathology. Both H. pylori-
infected humans and mice exhibit an overabundance of IL-22
(Zhuang et al. 2015), which stimulates gastric epithelial cells to
secrete CXCL2. CXCL2 then recruits myeloid-derived suppres-
sor cells that produce the proinflammatory proteins S100A8
and S100A9 and inhibit Th1 cell responses, thereby contribut-
ing to the development of H. pylori-associated gastritis (Zhuang
et al. 2015).
CONCLUSIONS
The intestinal tract is home to commensal bacteria and fungi
that have coevolved with the mammalian host. In order to
maintain intestinal homeostasis, the mucosal immune sys-
tem must balance between an appropriate response to dan-
gerous pathogens and an inappropriate response to commen-
sal microbiota that breach the epithelial barrier. IL-17 and IL-
22 have been shown to play a critical role in maintaining bar-
rier homeostasis against intestinal pathogens and commen-
sal bacteria. It is becoming increasingly apparent that bacte-
rial pathogens trigger a rapid IL-17 and IL-22-dependent in-
nate defense in the gut mucosa. In turn, intestinal produc-
tion of these cytokines seems to be regulated homeostatically
by interactions between the host and the intestinal microbiota
(e.g. SFB).
IL-17 and IL-22 enhance basic innate barrier defenses at mu-
cosal surfaces, such as antimicrobial peptide production and
neutrophil recruitment, i.e. rapidly occurring events that pre-
cede adaptive immunity. Although the functional spectra of
these cytokines overlap with regard to inducing an innate im-
mune response in epithelial cells, they are generally different.
IL-17 is largely proinflammatory and can be pathogenic, whereas
IL-22 primarily exhibits regenerative and protective roles. Nev-
ertheless, IL-22’s proinflammatory effects might contribute to
pathology, as could be the case in psoriasis (Zheng et al. 2007)
or IBD (Brand et al. 2006). Altogether, cytokines IL-17 and IL-22
provide barrier integrity against extracellular pathogens by (i) in-
structing innate immune responses in tissue cells, (ii) inducing
the recruitment of adaptive immune cells via epithelial-derived
chemokines and (iii) inducing regeneration of epithelial surfaces
after inflammation.
The IL-17 and IL-23 (i.e. the cytokine upstream of both IL-17
and IL-22) pathways are clinical targets for multiple inflamma-
tory diseases. For example, the antibody ustekinumab, which
neutralizes the p40 subunit of IL-23 and IL-12, is approved to
treat psoriasis and is showing benefit in clinical trials for Crohn’s
disease (Sandborn et al. 2008). Clinical data on the use of antibod-
ies specific to the IL-23 p19 subunit are beginning to emerge in
IBD and also show efficacy (Sandborn et al. 2008). IL-23-specific
antibodies are also highly efficacious in psoriasis, suggesting
that the efficacy achievedwith p40 inhibition is largely a result of
IL-23 inhibition (Leonardi et al. 2008; Papp et al. 2008; Croft, Bene-
dict and Ware 2013). Antibodies to IL-17A or IL-17RA are also
highly effective in psoriasis (Papp et al. 2012; Langley et al. 2014),
but surprisingly, they exacerbated Crohn’s disease in a subset of
patients (Hueber et al. 2012). Thus, although IL-23 is important
for production and maintenance of IL-17A and IL-17F, inhibition
of IL-17A or IL-17RA in patients with Crohn’s disease does not
phenocopy the effects observed with a p40 or p19 inhibitor. As
such, the mechanism(s) underlying the differential efficacy ob-
served in Crohn’s disease with inhibition of IL-17 versus IL-23 is
an important unanswered question.
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